Journal
BRITISH JOURNAL OF CANCER
Volume 106, Issue 10, Pages 1583-1586Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2012.144
Keywords
cholangiocarcinoma; skeletal muscle; cachexia; interleukin 6
Categories
Funding
- Roche from Alberta Health Services
- Alberta Heritage Foundation
- [NO1-CM62207]
Ask authors/readers for more resources
BACKGROUND: Cancer cachexia is characterised by skeletal muscle wasting; however, potential for muscle anabolism in patients with advanced cancer is unproven. METHODS: Quantitative analysis of computed tomography images for loss/gain of muscle in cholangiocarcinoma patients receiving selumetinib (AZD6244; ARRY-142886) in a Phase II study, compared with a separate standard therapy group. Selumetinib is an inhibitor of mitogen-activated protein/extracellular signal-regulated kinase and of interleukin-6 secretion, a putative mediator of muscle wasting. RESULTS: Overall, 84.2% of patients gained muscle after initiating selumetinib; mean overall gain of total lumbar muscle cross-sectional area was 13.6 cm(2)/100 days (similar to 2.3 kg on a whole-body basis). Cholangiocarcinoma patients who began standard treatment were markedly catabolic, with overall muscle loss of -7.3 cm(2)/100 days (similar to 1.2 kg) and by contrast only 16.7% of these patients gained muscle. CONCLUSION: Our findings suggest that selumetinib promotes muscle gain in patients with cholangiocarcinoma. Specific mechanisms and relevance for cachexia therapy remain to be investigated. British Journal of Cancer (2012) 106, 1583-1586. doi:10.1038/bjc.2012.144 www.bjcancer.com Published online 17 April 2012 (C) 2012 Cancer Research UK
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available